Neumora Therapeutics, Inc. announces multiple clinical data readouts expected in 2026, creating an opportunity for substantial value creation. KOASTAL-2 and -3 on track for consolidated topline readout in Q2 2026. Plans to conduct NMRA-215 clinical program in 2026 after positive preclinical data. Cash reserves expected to support operations into Q3 2027.

Neumora advances pipeline with key updates for 2026. Navacaprant joint readout planned for Q2 2026. NMRA-215 Phase 1 expected in H1 2026. Progressing Phase 1 for M4 PAM franchise. Positive results from Phase 1b study of NMRA-511 in Alzheimer’s disease agitation. Strong financial position to support operations.

Neumora Therapeutics aims to redefine neuroscience drug development with novel therapies. Pipeline includes programs targeting underserved neuropsychiatric disorders and neurodegenerative diseases. Supported by translational, clinical, and computational tools. Mission to bring forward improved treatment outcomes for patients with brain diseases.

Cautionary note regarding forward-looking statements. Neumora’s plans to redefine neuroscience drug development subject to risks and uncertainties. Risks include uncertainties of clinical drug development, regulatory approvals, side effects, and capital resources. Refer to SEC filings for detailed risk factors. Forward-looking statements speak as of the date hereof. Contact Helen Rubinstein for more information.

Read more at GlobeNewswire: Neumora Therapeutics Highlights 2026 Pipeline Strategy and